ALK-Abelló A/S (AKBLF)

Market Cap	7.55B +22.6%
Revenue (ttm)	1.01B +14.9%
Net Income	197.46M +36.6%
EPS	0.89 +38.3%
Shares Out	n/a
PE Ratio	38.24
Forward PE	32.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	37.92
Previous Close	38.89
Day's Range	37.92 - 37.92
52-Week Range	28.95 - 38.89
Beta	0.72
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About ALK-Abelló

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1923
• Employees: 2,759
• Stock Exchange: OTCMKTS
• Ticker Symbol: AKBLF

Financial Performance

In 2025, ALK-Abelló's revenue was 6.31 billion, an increase of 14.00% compared to the previous year's 5.54 billion. Earnings were 1.20 billion, an increase of 46.87%.

Financial numbers in DKK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 11, 2026

Data Sources Report a data error